“Clariness is very proud to support patient recruitment of critical Covid-19 studies. We’ve never had such an immediate impact on a disease that affects all of us. Our services speed up the studies we’re supporting,” says Dr Andree Beckerling, CEO of Clariness. The pharmaceutical industry is experiencing difficulty finding Covid-19 positive patients for their clinical trials.
Clariness has spent the past 15 years helping pharmaceutical companies find patients to participate in their clinical trials. Covid has not stopped us in this endeavour. Rather, it has focused our team members who are working diligently supporting recruitment efforts to find Covid patients and healthy volunteers for ongoing clinical trials.
The Covid-19 pandemic changed everything. We are living in a new normal where social distancing and mask wearing are de rigour; where quarantining and shutdown of businesses has caused staggering economic impact. As of mid-October, there have been more than 40 million cases of Covid-19 reported globally, with a tragic 1.1 million deaths.
The way back to normal is through science and medicine. Researchers around the world are busy working on vaccines to prevent Covid infection and treatments for patient with the virus. Researchers and doctors are conducting clinical trials looking at 45 different vaccines to prevent the spread of the disease. In addition, clinical trials are being conducted to test the efficacy and safety of numerous compounds, including antivirals, cell and gene therapies, immunomodulators, neutralising antibodies and other treatments. Some of the medicines under study for Covid are older drugs like hydroxychloroquine, interferon-beta and ritonavir/lopinavir as well as newer drugs like Remdesivir.
There are currently over 1,000 actively enrolling interventional Covid-related studies requiring a total of 1.3 million volunteers listed on ClinicalTrials.gov. This means that finding patients for a trial is highly competitive. Making it even more difficult, some protocols have very narrow windows for enrolment of a patient; for example, no longer than 48 hours from first symptoms. Clariness will continue to contribute driving the development of treatments and preventions to overcome this pandemic to success.